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ABSTRACT 
Coronavirus has become a major destructive 
virus for humans. The family of corona consist 
of pathogens of animals and humans, a recently 
developed COVID-19 infection. An outburst of 
2019 coronavirus diseases (COVID-19) spread 
from Wuhan, China to the entire world. More 
than 210 countries and territories are with 
confirmed cases of COVID-19 which is to be a 
most critical war for the world. Its first presence 
was found in animals then transmission 
occurred form animals to humans, and now 
human to human transmission is the most 
endeavor. No doubt every country's economy 
will be shrunk. To fight with COVID-19 one 
needs to know about these diseases and how can 
it be stopped form transmission. This review 
describes the virus, coronavirus, receptors and 
types, its genome sequence, life cycle, why 
diabetic and hypertension patients are more 
prone to these diseases, drug targets, detection, 
symptoms, and preventive measures. 
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INTRODUCTION 
 
The COVID-19 is a foremost damaging 
virus for the world. Currently, more than 210 
countries and territories are suffering from these 
tragedies [1]. Clinical trials are going on to develop 
the medications, vaccine form this viral infection. 
According to FDA currently, 10 therapeutic agents 
are in active trails and 15 therapeutic agents are 
under stages of development. There are some of the 
malarial drugs are used to treat these diseases but 
are not a permeant solution for these [2]. For 
targeting COVID-19, we need to know about why 
it is different from other viruses. Corona is of  
Coronaviridae family it possesses four genera of 
alpha, beta, gamma, and delta. Coronavirus belongs 
to the beta subfamily.   
 
WHAT IS VIRUS? 
 
Virus possesses a core of nucleic acid 
(DNA or RNA) which is surrounded by a coat of 
protein This core protein is also called a capsid. 
Coronavirus has a lipid envelop surrounding its 
capsid which occurs in rare viruses. There is a 
difference in virus ad cellular organisms as viruses 
cant reproduced on their own they needed to get 
into a living organism for their survival and make 
multiple copies of themselves in a host. The 
structure of a virus is simple than the cell [3,4]. It 
can trick the cells which they infected. It passes to 
the protective membrane of cells additionally it 
makes virions (viral nucleic acid surrounded by a 
capsid). Then these virions destroy the cell they 
enter [5,6]. Any viruses that infect bacteria inject 
their nucleic acid into bacterium while leaving 
external their capsid outside. The lipid layer of 
some viruses fuses with the cell membrane easily 
as the cell membrane is also of the lipid layer. Then 
the capsid and nucleic acid of viruses are released 
into the cell. The virus enters cells by endocytosis 
here the cell membrane forms a pocket that engulfs 
the virion. The pocket then gets separates from the 
cell membrane and forms a sac with the virion in 
the inner membrane. The virion afterward breaks 
out of the sac. Now once inside the cell, they divide 
and make new viral nucleic acid molecules and 
coats. These virions burst out of a cell, leading to 
destroying by cell lysis. By exocytosis, they release 
out of the cells by forming a sac which carries out 
virions and releases in outer content [7-9]. 
 
CORONAVIRUS 
 
Corona is of order Nidovirales and 
Coronaviridae family. Coronaviruses are only 
identified by electron microscope and are 
characterized by globular, enclosed virus particles 
with protruding surface projections, resembling the 
“corona” of the sun i.e crown as shown in figure 1. 
This virus infects various animal species probably 
cause of the newly recognized severe acute 
respiratory syndrome (SARS) with symptoms of 
cold, fever, shortness of breathing[10].  In humans, 
although it causes up to 32 percent of colds, and 
seldom cause lower respiratory tract disease. In 
contrast, coronaviruses origin upsetting epizootics 
of respiratory or enteric disease in livestock and 
poultry. Coronavirus needs host species [11,12]. 
Coronavirus is a single RNA (29891 nucleotides, 
encoding for 9860 amino acids), The ribonucleic 
acid strand structure contains main four proteins: 
spike (S) protein, nucleocapsid (N) protein, 
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membrane (M) protein, and the envelope (E) 
protein. The S protein is accountable for enabling 
entry of the CoV into a host cell and is a short 
intracellular tail, with a huge ectodomain that 
comprises of a receptor binding S1 subunit and a 
membrane-fusing S2 subunit. [13-15]. There are 
four genera of coronoaviruse: Alphacoronavirus 
(alphaCoV), Betacoronavirus (betaCoV), 
Deltacoronavirus (deltaCoV), and 
Gammacoronavirus (gammaCoV). This disease 
was first forecasted in 1931, and the first 
coronavirus was isolated from humans in 1965 
(HCoV-229E). Till 2002, an outbreak of severe 
acute respiratory syndrome(SARS) was only two 
human coronaviruses (HCoV) that were recognized 
– HCoV-229E and HCoV-OC43. SARS-CoV-2 
belongs to the betaCoVs category with form plump 
or elliptic and often pleomorphic possess a 
diameter of approximately 60–140 nm. It is 
sensitive to ultraviolet radiation and heat like other 
CoVs. Besides, these viruses can be effectively 
inactivated by ether (75%), ethanol, chlorine-
containing disinfectant, peroxyacetic acid, 
and chloroform except for chlorhexidine. In China 
89%  it bears nucleotide identity withSARS-like-
CoVZXC21 and 82% of human SARS-CoV. Hence 
it is known as SARS-Co V-2. Viruses responsible 
for  SARS-Co V-2 and CoVID-19 are 88% similar. 
 
 
Figure 1: Structure of coronavirus[10-15]. 
 
RECEPTORS OF CORONAVIRUS 
Coronavirus are of alpha, beta, gamma and deltacornoavirus as shown in table 1[16] 
 
Table 1: Receptors of coronavirus. 
Receptors of coronavirus 
Alphacoronaviruses 
Virus Receptor 
HCoV-229E APN 
HCoV-NL63 ACW2 
FIPV APN 
TGEV APN 
CCoV APN 
PEDV APN 
Betacoronaviruses 
MHV Mceacam 
BCoV N-acetyl-9-o-acetylneuraminic acid 
SARS-CoV ACE2 
MERS-CoV DDP4 
Gammacornonavirus 
BWCSW1 2,3 salic aicd 
AIBV HS 
Deltacornoavirus 
PDCoV DDP4 
BCHKU11 ACE2 
  
15 Page 13-21 © MAT Journals. All Rights Reserved 
 
Volume-2, Issue-2 (March-August, 2020)  
 
 
 
Journal of Molecular Pharmaceuticals and 
Regulatory Affairs 
 
www.matjournals.com 
 
GENOME SEQUENCES 
 
Coronaviruses genome contains a 5′ cap 
structure along with a 3′ poly (A) tail, permitting to 
as an mRNA for translation of polyproteins. 
Additionally, it contains a non-segmented, positive-
sense RNA genome of ~30 kb. At  5′ end of the 
genome, there is sequence and untranslated region 
(UTR) that encompasses several stem-loop 
structures essential for RNA replication and 
transcription. The 3′ UTR also holds RNA 
structures required for replication and synthesis of 
viral RNA. The association of the coronavirus 
genome is 5′-leader-UTR-replicase-S (Spike)-E 
(Envelope)-M (Membrane)-N (Nucleocapsid)-3′ 
UTR-poly (A) tail with accessory genes 
interspersed within the structural genes at the 3′ end 
of the genome [17,18]. The genome sequence is 
available at gene bank 
(MN988668 and NC_045512). The concluding 
genome SARS-CoV-2 consists of a single, 
positive-stranded RNA that is 29,811 nucleotides 
long, smashed down 8,903 (29.86%) adenosines, 
5,482 (18.39%) cytokines, 5,852 (19.63%) 
guanines, and 9,574 (32.12%) thymine’s.38 
 
TRANSMISSION 
 
The probable transmission is through 
closer contact with patients suffering from 
CoVID-19 would sneeze, cough, or speak the 
droplets will travel and enter to other humans. 
Touching the mouth, eyes with hand previously 
contaminated by infected surface or shaking 
hands with carrier person. From the first case in 
Wuhan, it has been investigated the incubation 
time is 3-7days to weeks with symptoms as 
usually a high fever, tracked by a headache and 
body aches. [19-23]. Animal and human 
coronavirus is shown in table 2. 
 
Table 2: Animal and Human Coronavirus. 
Animal coronavirus Human coronavirus 
Transmissible Gastroenteritis Virus (TGEV) and α-coronaviruses, HCoV-229E, and HCoV-NL63, 
 β-coronaviruses, HCoV-OC43, and HCoV-HKU1 
Porcine Epidemic Diarrhea Virus (PEDV) SARS-CoV, a group 2b β-coronavirus 
Porcine hemagglutinating encephalomyelitis virus (PHEV) MERS-CoV is a group 2c β-coronaviru 
Feline enteric coronavirus HKU4 and HKU5 
Feline Infectious Peritonitis Virus  
murine hepatitis virus (MHV)  
 
LIFE CYCLE OF CORONAVIRUS 
Life cycle of coronavirus is shown in figure 2. 
 
Figure 2: Life cycle of coronavirus. 
 
Attachment of the virions to the cell of the 
host is initiated by the S protein and its receptor to 
the binding site. S1 region of S protein where there 
is a site of receptor binding protein (RBD). For 
SARs these RBD is present in the C terminus of 
S1. Some of them utilize peptidase which is still 
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unclear. The receptor for entry of CoV is 
angiotensin-converting enzyme 2 which is a 
mettallocarboxypeptidase and homology to ACE; 
(which important for the renin-angiotensin 
system(RAS) in hypertension); this ACE2 is 
expressed in vascular endothelial cells, renal 
tubular epithelium and Leydig cells in testes. Also, 
some studies revealed its expression in the lungs, 
kidney, and gastrointestinal tract [24,25]. After the 
virus bind to this receptor, it gets to enter into the 
cytosol of the host. Now the cleavage of S protein 
by serine protease TMPRSS2. Cleavage occurs at 
two sites; first occurs as RBD separation and S 
fusion; second exposing S2 the fusion peptide 
[26,27]. The next step of translation gene encodes 
rep1a and rep lb, these express further the co-
terminal polyproteins, pp1a, and pp1b. the 
sequence utilized is “5’-UUUAAAC-3’” [28,29]. 
The pp1a and pp1b contain nsps 1-11 and 1-16. 
These polyprotein are cleaved into specific nsps. 
CoV encodeds two to three proteases  like papain-
like proteases (PLpro) by nsp3, and a serine type 
protease, the main protease, or Mpro, by nsp5. 
SARS-CoV and MERS-CoV, which only express 
one PLpro. The PLpros further cleave the nsp1/2, 
nsp2/3, and nsp3/4 boundaries, while the Mpro is 
responsible for the remaining 11 cleavage events 
[30,31]. Now there is presence of such an 
environment where RNA replication initiated and 
other enzyme domains are ready to initiate these 
processes [32].  The third step of RNA replication 
and transcription; where genomic and subgenomic 
are produced form synthesis of viral RNA. These 
both genomic and sub-genomic RNAs are produced 
over negative-strand intermediates[33]. In the 
5’UTR genome there are seven stem-loop AND 3’ 
UTR contains budged stem-loop. [34,35] Finally 
assembly and release occurs where the genome of 
CoV contains 5’ methylated cap and tail of 3’ 
polyadenylated tail allows RNA attach to the 
ribosomes for translation. mRNA codes for new 
viral proteins. Where N bind to genomic RNA, 
protein M in the endoplasmic reticulum, protein S 
after binding assembled nucleocapsid with helical 
twisted RNA in the ER lumen, and is enclosed. 
These further pass to the Golgi vesicles and 
exocytosis occurs, as shown in figure 3 [36,37].
 
 
Figure 3: Molecular-level life cycle of coronavirus. 
 
Angiotensin-converting enzyme 2 (ACE2) 
receptor makes an entry of coronavirus which 
further leads to the translation of RNA. ORF1a 
AND ORF1b are translated to produce a 
polyprotein pp1a and pp1b further proteases 
cleaved to form nonstructural proteins. 
Transcription further leads to translation and 
protein synthesis and they get assembled and 
budding formation occurs.At last through 
exocytosis, it infect other host cells [33-36]. 
DIABETIC AND HYPERTENSION 
PATIENTS ARE IN DANGER 
 
It is reported that if the increased 
occurrence of diabetes will upsurge the occurrence 
of infectious diseases and related comorbidities. 
Hyperglycemia in diabetes origin dysfunction of 
the immune response, due to which there no control 
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of pathogens invading the body. Due to low 
immunity, body is not able to produce the natural 
antibodies in the body. As due to specific 
immunization, only the natural antibodies are 
formed spontaneously. Hence diabetic are more 
prone to these disease [38-41]. 
Due to oxidative stress, a hypertensive 
stimuli, aldosterone, CNS inflammation leads to 
activation of sympathetic stimulation these 
activates the T cells and causes severe 
hypertension. In high blood pressure, initially there 
is tissue damage due to which it releases signals a 
localized immune responses. This immune 
response is more potent to cause organ damage 
[42,43].  ACE2 plays an important role for invasion 
of coronavirus in to the bodyand responsible for 
hypertension. ACE2 blockers can be used to treat 
coronavirus. But as discuss before these receptor 
are present over the body so it needs to be focused. 
 
DRUG TARGETS 
 
Spike protein is a main target for 
developing drug in COVID-19; where its 
interaction with ACE2 receptor can be hampered 
[44,45]. Antibodies form due to interaction of these 
protein and receptor can be developed which will 
be used as vaccine [46]. Antimalarial agent, 
chloroquine inhibits these infection by increasing 
the endosomal pH and alter the glycosylation of 
ACE2, which further interferes the binding of 
virus. Inhibitor such as SSAA09E2 are used to 
block the virus interaction and inhibit the protease 
which makes entry of virus in host cell [47,48]. 
Envelop protein play a role for coronaviruses 
assembly and budding process. Hexamethylene 
amiloride is used to target the protein ion channel 
protein [49]. Membrane protein have two profile 
incorporation of golgi complex in new virus and 
protein stabilization. So these also can be a target 
for  COVID-19 [50]. Nucelocapsid protein posses 
RNA binding with ribonucleoside hence inhibitors 
of RNA binding are designed [51]. Inhibitors of 
Hemagglutinin esterase and protease can be a 
target. Till date there are 658 clinical trail studies 
on going on COVID-19 [52]. 
 
DETECTION 
 
For detection of COVID-1. 9ELISA kits  
and RT-PCR are used. Principle of RT-PCR 
[53,54] is shown in figure 4. 
 
 
Figure 4: RT-PCR principle COVID-19. 
 
SYMPTOMS 
 
Initially it start with fever, fatigue, 
headache, dry cough. Then shortness of breath 
occurs. Patient should immediately admitted to 
hospital.  
A recent report clearly says that corona 
would be asymptomatic. Means patient suffering 
form corona would not know oneself [55-57].  
PREVENTIVE MEASURES 
 
According to WHO this disease is not air 
borne; first wash your hands quite often with hand 
wash or soap for 40 secs and. Used sanitizer to 
disinfect the hands till 20 secs formulation 
mentioned in table 3 which can only be prepared by 
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qualified pharmacist cost, labeling condition are 
mentioned in WHO guidelines. Do not touch your 
eyes, nose or mouth if your hands are not clean. 
Use masks while going out and immediately 
discard the mask after use. Avoid mass gathering. 
Self-isolation is the key for avoiding unusual 
attacks of COVID-19 [58-59]. 
 
Table 3: Formulation of hand rub by WHO recommendation. 
Formulation 1A Formulation 2A For  10 liters 1A For  10 liters 2A Category 
Ethanol 96% Isopropyl alcohol 8333ml 7515 ml Disinfectant 
Hydrogen peroxide 3% Hydrogen peroxide 3% 417ml 417ml Inactive bacterial spores 
Glycerol  98% Glycerol  98% 145ml 145ml Humectant 
Sterile or distill water Sterile or distill water 1105 1105 Vehicle 
 
CONCLUSION 
 
Coronavirus been a destructive viral 
infection which uttermost spread all over the 
world/.  Future investigation on coronaviruses in 
aspects of drug development will be in influence. 
First and foremost thing is to understand the viral 
structure and transmission. Its life cycle explains it 
process of transmission and how can one develop 
the vaccines and medications. These review 
explains short about the all necessary things under 
consideration of these infection. occurrence of 
these disease in diabetic and hypertension. The 
diagnosis and prevention of disease is also been 
verdict in these review. Further these will be 
helpful to develop the drug for these disasters. 
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